drugset
drugset / Trial / NCT07389187

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT07389187 ↗

Phase 0 Not yet recruiting 10 enrolled Shanghai Changzheng Hospital
NaSingle-groupOpen-labelTreatment

Summary

This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior therapies. Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period.

Timeline

Start
2026-02
Primary completion
2026-12
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LC-K76 Unknown 1.2 g Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Background Degarelix Other / unclassified — —
Background Goserelin Other / unclassified — —
Background Leuprolide Other / unclassified — —
Background Triptorelin Other / unclassified — —

Indications

castration-resistant prostate carcinoma